Ulcerative colitis is the lead indication for Odyssey Therapeutics’ internally discovered lead drug candidate. With the IPO proceeds, Odyssey plans mid-stage clinical trials evaluating the small molecule in combination with Takeda’s Entyvio and as a monotherapy.
The post Odyssey’s IPO Brings In $304M for Quest to Develop Better Immunology Drugs appeared first on MedCity News.
